Researcher
Cynthia Kenyon
Last updated Sun May 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Background
Cynthia Kenyon trained at MIT and Cambridge. As a faculty member at UCSF she made the foundational discovery of the daf-2 lifespan mutants in C. elegans in 1993. Since 2014, she has been Vice President of Aging Research at Calico, the Alphabet-funded longevity biotech.
Key contributions
- daf-2 worms live twice as long as wild type. daf-2 encodes the insulin/IGF-1 receptor in C. elegans, and reduced signalling activates the FOXO-orthologue DAF-16, turning on a longevity-protective gene programme.
- Established that aging is regulated by signalling pathways, not just passive wear and tear — arguably the single most important insight in modern geroscience.
- Showed germline-soma interactions in lifespan determination.
- Demonstrated conservation of the IIS axis from worms to mammals.
Influence
The daf-2 discovery anchors the entire downstream field of insulin/IGF-1 signalling, mTOR pathway, FOXO transcription factors, and the “druggable longevity” framework that motivates rapamycin, metformin, and GLP-1-agonist work today.
Related entries
Insulin/IGF-1 signalling, FOXO transcription factors, Calico (company).
References
- Kenyon, C. et al. A C. elegans mutant that lives twice as long as wild type. Nature 366, 461–464 (1993).